Sunday, January 11, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Enhabit NYSE EHAB Earnings Report Preview and Analysis

Elaine Mendonca by Elaine Mendonca
March 5, 2024
in Breaking News
0
Finances
0
SHARES
6
VIEWS
Share on FacebookShare on Twitter

Enhabit (NYSE: EHAB) is set to unveil its latest earnings report on March 6, 2024. Analysts are predicting an EPS of $0.03 for this quarter, with investors eagerly awaiting not only to see if Enhabit surpasses this estimate but also for positive guidance on future growth.

In the previous quarter, Enhabit missed EPS expectations by $0.03, yet the stock price soared by 16.02% the next day. Here is a breakdown of Enhabit’s past performance and the resulting price fluctuations:

– Q3 2023: EPS Estimate 0.06, EPS Actual 0.03, Price Change 16.0%
– Q2 2023: EPS Estimate 0.14, EPS Actual 0.04, Price Change -14.0%
– Q1 2023: EPS Estimate 0.15, EPS Actual 0.09, Price Change -9.0%
– Q4 2022: EPS Estimate 0.23, EPS Actual 0.32, Price Change 12.0%

Enhabit’s shares were trading at $8.22 as of March 4, marking a 41.09% decline over the past year. With this negative trajectory, long-term investors may be approaching the upcoming earnings release with caution.

For more information on Enhabit’s financial performance and earnings updates, visit their financials and quarterly results page.

EHAB Stock Price Decline on March 5, 2024: Analysis and Potential Buying Opportunity

On March 5, 2024, EHAB stock experienced a decline in its price performance. Trading near the bottom of its 52-week range and below its 200-day simple moving average, the stock opened at $8.17, which was $0.05 lower than its previous close.

Throughout the trading day, EHAB shares saw a decrease of $0.16, representing a 1.89% drop in its price. This downward movement indicates a lack of positive momentum for the stock on that particular day.

Investors and analysts may view this decline as a potential opportunity to buy EHAB shares at a lower price, especially if they believe in the long-term growth prospects of the company. However, it is important to conduct thorough research and analysis before making any investment decisions.

EHAB Stock Performance Analysis: Mixed Results on March 5, 2024

On March 5, 2024, EHAB stock experienced mixed performances based on the financial data provided by CNN Money. The company’s total revenue for the past year was reported at $1.07 billion, with a decrease of 3.21% compared to the previous year. However, the total revenue remained flat since the last quarter, with a reported figure of $258.30 million.

In terms of net income, EHAB reported a net loss of $40.40 million for the past year, representing a significant decrease of 136.36% compared to the previous year. On a positive note, the net income for the last quarter showed an improvement, with a net loss of $2.40 million, indicating an increase of 96.77% since the previous quarter.

Earnings per share (EPS) also showed a decline for EHAB stock. The EPS for the past year was reported at -$0.81, reflecting a decrease of 102.83% compared to the previous year. However, the EPS for the last quarter showed an improvement, with a reported figure of -$0.05, representing an increase of 96.78% since the previous quarter.

Overall, EHAB stock performances on March 5, 2024, were a mix of both positive and negative trends. Investors and analysts will likely closely monitor EHAB’s financial performance in the coming quarters to assess the company’s growth prospects and potential for future profitability.

Tags: EHAB
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Finance analyst

Guggenheim Analyst Reiterates Buy Rating on Prime Medicine with Revised Price Target

Investings on laptop and finances

LB Foster Company Reports Diverse Financial Performance in Q4 FY23 and Provides FY24 Outlook

Unraveling the Potential of AI in Tailoring Healthcare Solutions

Axogen Inc Reports Impressive Financial Success in Q4 2023

Recommended

Transportation Stock Bull Market

JR Kyushu Implements AIPowered AMD Kria K26 SOM for Enhanced Track Inspection Efficiency and Safety

2 years ago
TMUS stock news

Wedbush Analyst Maintains Outperform Rating and Raises Price Target for Global Payments

2 years ago
JD.com Stock

JD.com Shares Surge on Robust Performance and Strategic Moves

3 months ago
Mobile-handsets

Palantir Technologies Reveals Revenue Projections for Q1 2024

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Procter & Gamble Shares Approach a Critical Juncture

Vital Farms Shares Face Headwinds Amid Forecast Revisions and Insider Activity

Palantir Shares: A Wall Street Divide and a Bold New Price Target

Nvidia Accelerates AI Dominance with Early Chip Launch and Strategic Expansions

Netflix Shares Under Pressure Amid High-Stakes Acquisition Battle

Marvell Technology Shares Face Conflicting Market Cues

Trending

Viking Therapeutics Stock
Analysis

Viking Therapeutics: A Tale of Clinical Progress and Insider Selling

by Felix Baarz
January 11, 2026
0

The shares of Viking Therapeutics, a biotechnology firm, are presenting investors with a conflicting narrative this week....

Astera Labs Stock

Astera Labs Shares Face Selling Pressure Amid Strong Fundamentals

January 11, 2026
Realty Income Stock

Institutional Investors Increase Stakes in Realty Income Amid Strategic Refinancing

January 11, 2026
Procter & Gamble Stock

Procter & Gamble Shares Approach a Critical Juncture

January 11, 2026
Vital Farms Stock

Vital Farms Shares Face Headwinds Amid Forecast Revisions and Insider Activity

January 11, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Viking Therapeutics: A Tale of Clinical Progress and Insider Selling
  • Astera Labs Shares Face Selling Pressure Amid Strong Fundamentals
  • Institutional Investors Increase Stakes in Realty Income Amid Strategic Refinancing

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com